A Phase Ib/II Study of AK104 and AK117 in Combination With or Without Chemotherapy in Advanced Malignant Tumors

• Status: Not yet recruiting
• Trial end date: 2024-03-01

Summary

Phase Ib/II open label, multicenter study to evaluate the efficacy and safety of AK104 (anti-PD-1 and CTLA-4 bispecific antibody) and AK117#AntiCD47 Antibody# combined with or without chemotherapy in advanced malignant tumors

• Phase: Phase 1/Phase 2

Details

• Lead Sponsor: Akeso
• Treatments: Capecitabine; Docetaxel; Irinotecan; Oxaliplatin; Paclitaxel